Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans

• A. L. De Sousa-Coelho,
• A. L. De Sousa-Coelho,
• A. L. De Sousa-Coelho,
• R. Rodriguez-Rodriguez,
• R. Rodriguez-Rodriguez,
• S. Softic,
• J. W. Jonker,
• J. Relat,
• J. Relat,
• J. Relat

Affiliations

A. L. De Sousa-Coelho

Escola Superior de Saúde (ESS), Universidade do Algarve (UAlg), Faro, Portugal

A. L. De Sousa-Coelho

Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve (UAlg), Faro, Portugal

A. L. De Sousa-Coelho

Algarve Biomedical Center (ABC), Faro, Portugal

R. Rodriguez-Rodriguez

Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain

R. Rodriguez-Rodriguez

Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain

S. Softic

Department of Pediatrics, Division of Pediatric Gastroenterology, Kentucky Children’s Hospital, and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, United States

J. W. Jonker

Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

J. Relat

Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain

J. Relat

Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Santa Coloma de Gramenet, Spain

J. Relat

Institute of Nutrition and Food Safety of the University of Barcelona (INSA-UB), Santa Coloma de Gramenet, Spain